Review
doi: 10.2174/187152607780090739.
Recent developments in the virology and antiviral research of severe acute respiratory syndrome coronavirus
Affiliations
- PMID: 17346209
- DOI: 10.2174/187152607780090739
Item in Clipboard
Review
Recent developments in the virology and antiviral research of severe acute respiratory syndrome coronavirus
Infect Disord Drug Targets.
2007 Mar.
Abstract
This article summarizes the significant developments and new discoveries in both the virology and antiviral research associated with the severe acute respiratory syndrome coronavirus (SARS CoV) that were reported in 2005 and 2006. Areas reviewed include genomic studies and the identification of bat-SARS CoV, spike protein and host cell entry, nucleocapsid protein, accessory proteins, non-structural proteins of the replicase complex, viral proteases and their inhibitors, and clinical treatment of SARS with ribavirin.
Similar articles
-
An overall picture of SARS coronavirus (SARS-CoV) genome-encoded major proteins: structures, functions and drug development.Curr Pharm Des. 2006;12(35):4539-53. doi: 10.2174/138161206779010459. Curr Pharm Des. 2006. PMID: 17168760 Review.
-
Severe acute respiratory syndrome coronavirus entry as a target of antiviral therapies.Antivir Ther. 2007;12(4 Pt B):639-50. Antivir Ther. 2007. PMID: 17944271 Review.
-
Recent patents on treatment of severe acute respiratory syndrome (SARS).Recent Pat Antiinfect Drug Discov. 2007 Jan;2(1):1-10. doi: 10.2174/157489107779561698. Recent Pat Antiinfect Drug Discov. 2007. PMID: 18221160 Review.
-
From SARS and MERS CoVs to SARS-CoV-2: Moving toward more biased codon usage in viral structural and nonstructural genes.J Med Virol. 2020 Jun;92(6):660-666. doi: 10.1002/jmv.25754. Epub 2020 Mar 16. J Med Virol. 2020. PMID: 32159237 Free PMC article.
-
The spike protein of SARS-CoV--a target for vaccine and therapeutic development.Nat Rev Microbiol. 2009 Mar;7(3):226-36. doi: 10.1038/nrmicro2090. Epub 2009 Feb 9. Nat Rev Microbiol. 2009. PMID: 19198616 Free PMC article. Review.
Cited by
-
Targeting ACE2-RBD Interaction as a Platform for COVID-19 Therapeutics: Development and Drug-Repurposing Screen of an AlphaLISA Proximity Assay.ACS Pharmacol Transl Sci. 2020 Nov 17;3(6):1352-1360. doi: 10.1021/acsptsci.0c00161. eCollection 2020 Dec 11. ACS Pharmacol Transl Sci. 2020. PMID: 33330843 Free PMC article.
-
Targeting ACE2-RBD interaction as a platform for COVID19 therapeutics: Development and drug repurposing screen of an AlphaLISA proximity assay.bioRxiv [Preprint]. 2020 Jun 16:2020.06.16.154708. doi: 10.1101/2020.06.16.154708. bioRxiv. 2020. Update in: ACS Pharmacol Transl Sci. 2020 Nov 17;3(6):1352-1360. doi: 10.1021/acsptsci.0c00161 PMID: 32577632 Free PMC article. Updated. Preprint.
-
Discovery, synthesis, and structure-based optimization of a series of N-(tert-butyl)-2-(N-arylamido)-2-(pyridin-3-yl) acetamides (ML188) as potent noncovalent small molecule inhibitors of the severe acute respiratory syndrome coronavirus (SARS-CoV) 3CL protease.J Med Chem. 2013 Jan 24;56(2):534-46. doi: 10.1021/jm301580n. Epub 2013 Jan 3. J Med Chem. 2013. PMID: 23231439 Free PMC article.
-
SARS-CoV nucleocapsid protein interacts with cellular pyruvate kinase protein and inhibits its activity.Arch Virol. 2012 Apr;157(4):635-45. doi: 10.1007/s00705-011-1221-7. Epub 2012 Jan 6. Arch Virol. 2012. PMID: 22222284 Free PMC article.
-
Inhibitors of SARS-3CLpro: virtual screening, biological evaluation, and molecular dynamics simulation studies.J Chem Inf Model. 2011 Jun 27;51(6):1376-92. doi: 10.1021/ci1004916. Epub 2011 May 23. J Chem Inf Model. 2011. PMID: 21604711 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous
